<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569579</url>
  </required_header>
  <id_info>
    <org_study_id>179DDI18002</org_study_id>
    <nct_id>NCT03569579</nct_id>
  </id_info>
  <brief_title>CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of D797 on Pharmacokinetics of D324 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction between D797 of
      D324 in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of twenty(20), following treatments are administered dosing in each
      period and wash-out period is a minimum of 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">June 4, 2018</completion_date>
  <primary_completion_date type="Actual">May 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Area under the plasma concentration of Memantine versus time curve from time zero to time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Maximum plasma concentration of Memantine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Area under the plasma concentration of Memantine versus time curve from time zero to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Time to maximum concentration of of Memantine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Apparent terminal half-life of Memantine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Total body clearance of Memantine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Memantine</measure>
    <time_frame>1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h</time_frame>
    <description>Apparent volume of distribution of Memantine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.
Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
Each treatment period was separated by a washout period of at least 21 dyas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1(Treatment B/Treatment A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.
Each treatment period was separated by a washout period of at least 21 dyas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Tab. 10mg</intervention_name>
    <description>Memantine Tab. 10mg* 2T/day, QD, PO</description>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_label>Group 1(Treatment B/Treatment A)</arm_group_label>
    <other_name>Ebixa Tab. 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Tab. 10mg + Donepezil Tab. 10mg</intervention_name>
    <description>Memantine Tab. 10mg* 2T/day + Donepezil Tab. 10mg * 1T/day, QD, PO</description>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_label>Group 1(Treatment B/Treatment A)</arm_group_label>
    <other_name>Ebixa Tab. 10mg + Aricept Tab. 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy adult whose age is over 19 years old when visiting for initial screening
             test

          2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg
             (Body mass index (BMI) = weight (kg) / height (m)^2)

          3. A person with no congenital or chronic disease in three years, no history of symptoms
             in internal treatment, or no knowledge in the area

          4. Due to the special characteristics of drugs, the participators must be qualified to do
             the clinical screening after examined through hematology test and blood chemistry
             analysis, urinary test, the electrocardiogram (ECG), and etc.

          5. The participants must be volunteered and sign in an informed consent document proven
             by Chonbuk National University IRB before joining a study to show that he was given
             informed the purpose of tests and the special characteristics of drugs.

          6. The participants must have an ability and willingness to participate throughout the
             entire trials

        Exclusion Criteria:

          1. A person who had a history or symptoms of clinically aware of blood, kidney, internal
             secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous,
             or allergic(except subclinical seasonal allergies that is not treated at injecion)
             desease.

          2. Who had a gistory of gastrointestinal related disease which can be affected the drug
             absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's
             disease) or surgeries (except a simple appendectomy or herniotomy)

          3. Who had following results after examination

             a. ALT or AST &gt; twice higher than normal value

          4. Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup
             of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%)
             (125 mL) = 12g)

          5. Who participated other clinical test or took testing bioequivalence drugs in 3 months
             before the first clinical drug trial.

          6. Whose blood pressure &lt; 100 or ≥140(systolic blood pressure) or &lt; 70 or ≥ 90(diastolic
             blood pressure)

          7. Who had a medical history of alcohol and drug abuses.

          8. Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion)
             in 30 days before the first taking of clinical testing durg.

          9. Who smokes more than 10 eigarettes per day.

         10. Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very
             first clinical testing drug.

         11. Who participated in whole blood donation in 2 months before the first taking of
             clinical testing drugs or platelet donations in 1 month before the first taking to
             clinical testing drugs.

         12. Who has a potent to increase a danger by participating in the clinical trials or sho
             can interrupt interpretin test results by having serious or chronic medical and mental
             status or having issues in results of the screening examination.

         13. Who has a histroy of an extreme sensitivity of drugs that contain donepezil
             hydrochloride, piperidine derivatives, memantine hydrochloride drugs.

             Who has a serious heart failure or a congestive heart failure that must be
             drug-treated

         14. Who has a Pregnant or potentially pregnant.

         15. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose
             malabsorption or genetic disorders.

         16. A patient with severe hepatopathy

         17. A patient with moderate nephropathy.

         18. A person who is not determined unsuitable to participate in this test by the
             researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Ho Jang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 15, 2018</last_update_submitted>
  <last_update_submitted_qc>June 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

